President & CEO Of BioBusiness.TV

Shows

Mayo Clinic Health Matters Innovation is transforming patient care in Florida, beyondThe COVID-19 pandemic has pushed medical research and patient care to new levels. High-volume testing for COVID-19, researching convalescent plasma and monitoring patients at home are just a few of the challenges met by Mayo Clinic in Florida in 2020. Dr. Kent Thielen, CEO of Mayo Clinic in Florida, says they also are looking ahead as the campus continues to grow. He highlights the Lung Restoration Center, the Discovery and Innovation Center, the BioBusiness Incubator and the integrated oncology facility as examples of accelerated programs. In the this Mayo Clinic Q&A podcast, Dr. Thielen expands on the cultu...

2021-01-1519 min

Mayo Clinic Q&A Innovation is transforming patient care in Florida, beyondThe COVID-19 pandemic has pushed medical research and patient care to new levels. High-volume testing for COVID-19, researching convalescent plasma and monitoring patients at home are just a few of the challenges met by Mayo Clinic in Florida in 2020. Dr. Kent Thielen, CEO of Mayo Clinic in Florida, says they also are looking ahead as the campus continues to grow. He highlights the Lung Restoration Center, the Discovery and Innovation Center, the BioBusiness Incubator and the integrated oncology facility as examples of accelerated programs. In the this Mayo Clinic Q&A podcast, Dr. Thielen expands on the cultu...

2021-01-1519 min

BioBusiness.TV, the podcast! ver2 ASBMR Review - Part 1: AMGN Makes NewsYou are Watching: Post ASBMR Review: Amgen's Denosumab Lowers Fracture Risk, Makes the News at the American Society for Bone and Mineral Research (ASBMR) meeting. Mike is back from a very exciting American Society for Bone and Mineral Research (ASBMR) meeting in Montreal. Amgen made the news with the results of its phase 3 trial for Denosumab. Mike explains Denosumab sets a new standard for a highly efficacious, safe, and convenient treatment for a disease that has a very high unmet need, despite its prevalence. Mike and Jean-Loup comparison Denosumab to Novartis' Reclast and other Bisphosphonates - looking at safety, tolerability...

2008-09-1901 min

BioBusiness.TV, the podcast! ver2 ASBMR Review - Part 2: AMGN StrategyYou are Watching: Post ASBMR Review: Denosumab to Seize Low Hanging Fruit in Osteoporosis Market, with the Potential to Become 1st Line Treatment. Amgen's Currently Inexpensive Shares to Gain 20 points. After reviewing the Denosumab data released at the ASBMR meeting, it looks like Amgen's osteoporosis drug will be a 2nd line treatment. With 50% of osteoporosis patients going off their bisphosphonates in their fisrt year, Mike King thinks there is a low hanging fruit there. Mike also thinks the drug's profile could allow it to quickly become a first line treatment. Jean-Loup and Mike look at the market, Amgen's pricing for...

2008-09-1910 min

BioBusiness.TV, the podcast! ver2 ASBMR Review - Part 3: Pfizer, MerckYou are Watching: Post ASBMR Review: A quick look Pfizer's Fablyn, and Merck Odanacatib. Mike and Jean-Loup take a quick look at some of the other data released at the American Society for Bone and Mineral Research Meeting in Montreal. They review Pfizer's PEARL study for the drug Fablyn, and Merck's phase 2 Odanacatib. This interview was conducted at the NASDAQ Marketsite, on September 19th, 2008, in New York City. Featuring: * Michael King, Director of Research, Rodman & Renshaw * Jean-Loup Romet-Lemonne, President & CEO of BioBusiness.TV DISCLAIMER: BIOBUSINESS.TV IS AN INDEPENDENT MEDIA, AND A PLATFORM FOR THE EXCHANGE OF IDEAS AND OPINIONS...

2008-09-1900 min

BioBusiness.TV, the podcast! ver2 TARG CEO Interview - Part 1You are Watching: Targanta's Antibiotic Shows Promise, And Overcomes the Challenges it Faced When Previously Developped at Lilly and InterMune Oritavancin is Targanta's lead compound. Initially developped at Lilly, it was then sold to InterMune, and picked up by Targanta in an equity deal. Mark Leuchtenberger explains the history of the drug, and in doing so faces further probe from Joel Sendek as to the corporate and medical challenges the drug had to face in its earlier days. Mark explains how they were overcome in Targanta's hands, and the true potential of the was drug unlocked. This interview was conducted...

2008-09-1806 min

BioBusiness.TV, the podcast! ver2 TARG CEO Interview - Part 2You are Watching: Targanta Confident and Prepared for FDA Panel Review of Lead Compound Oritavancin Mark and Joel delve into the clincal trials and regulatory process, around Targanta's Lead compound Oritavancin. Mark describes the current response of the FDA, and completed clinial site audits. He then continues to explain his team is expecting a panel meeting and is fully prepared to assit the panel's review of the drug. This panel could be expected as early as November of this year. When Joel inquires about the release of simplified data, which might differentiate Oritavancin for its competitors, Mark tells him about...

2008-09-1801 min

BioBusiness.TV, the podcast! ver2 TARG CEO Interview - Part 3You are Watching: Targanta Attacking $1.2Bn Antibiotic Market with Resistance Adverse Drug, Do-or-Die! Mark and Joel review the competitive landscape for Targanta's Antibiotic and Lead Compound, Oritavancin. Key differentiators include shorter course of treatment, lack of monitoring and dosing adjustment, efficacy and coverage. With a growing $1.2bn market, Mark still sees an unmet medical need in resistance adverse antibiotics, which Targanta is looking to address with focus, passion, and a Do-or-Die attitude. A Phase 3 trial, validating a single dose treatment against a standard of care competitor is expected to run next year. This interview was conducted at the NASDAQ Marketsite...

2008-09-1801 min

BioBusiness.TV, the podcast! ver2 ALXA CEO Interview - Part 1You are Watching: Alexza's Staccato: Vaporized Drugs in Multiple Indications, with a Safe and Effective Profile The Staccato system combines drug and device to provide a quick and convenient relief for patients with acute and intermittent conditions. Tom King (Alexza) and Ted Tenthoff (Piper Jaffray) explore the technology, mechanism of action, and safety profile. Tom and Ted to discuss the drugs in the pipeline and the indications, which include acute agitation associated with schizophrenia or bipolar disorders, breakthrough pain, panic attacks, and insomnia. They review the clinical data, and path for regulatory approval, in what Tom King calls a "crisp...

2008-09-1701 min

BioBusiness.TV, the podcast! ver2 ALXA CEO Interview - Part 2You are Watching: Alexza's Eulogistic Symphony Deal, Partnering and Sales Strategies, and Cash 'till the Summer of 2010 Ted Tenthoff asks Tom King of Alexza's partnering strategy. Alexza will develop its own compounds for Psychiatry but will seek to partner in other areas, such as sleep - where Alexza is working with Endo Pharmaceuticals. Tom explains Alexza's strong cash position, and the value of the Symphony transaction, which ultimately led to the development of 3 phase 3 products. Tom and Ted review other financing vehicles used by Alexza, and the production capabilities of the new Mountain View, CA GMP facility. Finally Ted asks...

2008-09-1710 min

BioBusiness.TV, the podcast! ver2 Making Money in Biotech - Part 1You are Watching: Making Money in Biotech, the JMP Securities Way - Part I: State of the Industry Mid Year Report The biotech sector is driven by news flow, because it has the power to change the value of companies, and put (more) money in your wallet. Charles Duncan and Jean-Loup discuss the performance of the Biotech industry in 2008 to this day, and the potential impact of news to come in the remainder of this year in the coming months. Despite the very challenging conditions, biotech outperformed. Charles and Jean-Loup also touch on the industry's relative strength in the tough...

2008-09-0901 min

BioBusiness.TV, the podcast! ver2 Making Money in Biotech - Part 2You are Watching: Making Money in Biotech, the JMP Securities Way - Part II: Finding the Tipping Point Which companies are likely to have news that can double the value your shares? Charles Duncan looks at the less obvious stock picks that could provide you with the most bang for your buck. His equation for determining the best opportunities incorporates variables such as lack of revenue (yes he means lack of), products that are owned outright and about to get significant clinical data, no FDA risk, and good cash position. This interview was conducted at the NASDAQ Marketsite, on September 9...

2008-09-0905 min

BioBusiness.TV, the podcast! ver2 Making Money in Biotech - Part 3You are Watching: Making Money in Biotech, the JMP Securities Way - Part III: A few Stock Picks Allos, Cytokinetics, Orexigen, and Sangamo or just a few of JMP Securities stock picks for the end of the year. Charles Duncan explains how they are at a pivotal moment in their growth, and therefore best positioned to generate large returns for investors. Charles gives us some details about the company, the ongoing clinical trials, and the type of news we should expect in the months to come. This interview was conducted at the NASDAQ Marketsite, on September 9th, 2008, in New York...

2008-09-0901 min

BioBusiness.TV, the podcast! ver2 PARD CEO Interview - Part 1You are Watching: Poniard’s Platinum Compound for Oncology, A Winning Design for its Clinical Trial How does one go about creating value with a platinum compound? In this interview Mike King asks Jerry McMahon of his rather broad use of Picoplatin in Oncology. They review the SPEAR clinical trial in Small Cell Lung Cancer, its design, endpoints, timeline, competitive landscape, and favorability with the FDA. This interview was conducted at the NASDAQ Marketsite, on September 8th, 2008, in New York City. Featuring: * Jerry McMahon, Chairman and Chief Executive Officer, Poniard Pharmaceuticals * Michael King, Director of Research, Rodman & Renshaw DISCLAIMER: BIOBUSINESS.TV...

2008-09-0808 min

BioBusiness.TV, the podcast! ver2 PARD CEO Interview - Part 2You are Watching: Picoplatin in Colorectal, Prostate, Ovarian Cancer and NSCLC, and Poniard’s $100M Cash Position Poniard has begun clinical trials of it’s Picoplatin in combination with other standard of care therapies. Jerry McMahon and Mike King discuss these indications and the different strategies for each one. Jerry tells us about the data presented in these trials at the latest ASCO meetings. Finally they review Poniard’s very attractive cash position, and its plans for partnering in the years to come. This interview was conducted at the NASDAQ Marketsite, on September 8th, 2008, in New York City. Featuring: * Jerry McMaho...

2008-09-0801 min

BioBusiness.TV, the podcast! ver2 NLTX CEO Interview - Part 1You are Watching: Nile’s Peptide for Heart Failure to Achieve Superiority through Hemodynamic and Renal Action Peter Strumph describes Nile Therapeutics’ CD-NP peptide for the treatment of Acute Heart Failure, and the competitive landscape. Matt Kaplan asks him about the market size, existing products, and unmet needs. In answering these questions, Peter reviews the mechanisms of action of the peptides on the market and compares their mechanisms of action to Nile’s CDNP which is expected to have more potent Hemodynamic and Renal effects. This interview was conducted at the NASDAQ Marketsite, on September 3rd, 2008, in New York City. Featur...

2008-09-0305 min

BioBusiness.TV, the podcast! ver2 NLTX CEO Interview - Part 2You are Watching: Nile’s CD-NP Phase 3 Strategy, and Secondary Pipeline Products, and 8 Person Team Peter Strumph lines up the milestones to come for Nile’s lead compound CD-NP and gives us a closer look at his strategy for determining the right dosage in Phase 2, in order to adequately prepare his Phase 3. Peter and Matt then discuss CU-NP and 2NTX-99, other pipeline products, Nile’s 8 person team and leverage model, as well as future in-licensing. This interview was conducted at the NASDAQ Marketsite, on September 3rd, 2008, in New York City. Featuring: * Peter M. Strumph, CEO, Nile Therapeutics * Matthew L. Kaplan, Managi...

2008-09-0301 min

BioBusiness.TV, the podcast! ver2 Store Your Neuronal Stem CellsYou are Watching: Award Winning NeuroBank Team stores your Neuronal Stem Cells NeuroBank was recently awarded the third prize in the Moot Corp Competition dubbed "The Super Bowl of World Business Plan Competition". Their business model relies on a process of extraction, isolation, purification, expansion and storage of adult neural stem cells. Bill Kridel, stem cell expert, interviews the winning team. They discuss Neurobank’s proprietary process, future uses of neuronal stem cells, viability of cryogenically stored cells, cost for and risk to patient, target markets, and customer acquisition. This interview was conducted at the NASDAQ Marketsite, on August 15th, 2008, in...

2008-08-1501 min

BioBusiness.TV, the podcast! ver2 Visionaries - Kridel on M&AYou are Watching: Visionaries: Bill Kridel on the Role of M&A Today. Bill Kridel discusses the strategic and rescue role of M&A today. Many companies leverage M&A for geographic and portfolio reasons - looking at some of the latest deals (Roche and Genentech, Daiichi and Ranbaxy). With the current market conditions M&A propositions from larger companies are becoming increasingly attractive. This interview was conducted at the NASDAQ Marketsite, on July 23rd, 2008, in New York City. Featuring: * William Kridel, Managing Director at Ferghana Partners Group * Jean-Loup Romet-Lemonne, President & CEO of BioBusiness.TV DISCLAIMER: BIOBUSINESS.TV IS AN...

2008-07-2301 min

BioBusiness.TV, the podcast! ver2 Visionaries - Kridel on Biotech in 20 YearsYou are Watching: Visionaries: Bill Kridel on Biotech in 20 Years, Regenerative Medicine, Biomarkers, Personalized Medicine. Bill Kridel foresees three great tsunami that are bound to change the biotech industry and the quality of healthcare. These are regenerative medicine, biomarkers and molecular diagnostics, and personalized medicine. Bill also discusses pharma's solutions to increase innovation, and the increased international competitivity. This interview was conducted at the NASDAQ Marketsite, on July 23rd, 2008, in New York City. Featuring: * William Kridel, Managing Director at Ferghana Partners Group * Jean-Loup Romet-Lemonne, President & CEO of BioBusiness.TV DISCLAIMER: BIOBUSINESS.TV IS AN INDEPENDENT MEDIA, AND A PLATFORM FOR...

2008-07-2301 min

BioBusiness.TV, the podcast! ver2 Stem Cell Business Models with Bill KridelYou are Watching: Stem Cells Business Models, FDA Initiatives, Companies, and Funds, with Bill Kridel Bill Kridel compares stem cell business models that rely on allogenic vs autologous cells and discusses their market potential. He also touches at the various uses of stem cells, the need for standards of uniformity, FDA Initiatives, companies to focus on, and specialized funds. This interview was conducted at the NASDAQ Marketsite, on July 23rd, 2008, in New York City. Featuring: * William Kridel, Managing Director at Ferghana Partners Group * Jean-Loup Romet-Lemonne, President & CEO of BioBusiness.TV DISCLAIMER: BIOBUSINESS.TV IS AN INDEPENDENT MEDIA, AND A PLATFORM...

2008-07-2306 min

BioBusiness.TV, the podcast! ver2 Vivalis CSO Interview - Embryonic Stem Cell TechnologyYou are Watching: Vivalis uses Embryonic Stem Cell Technology to Enable Vaccine and Antibody Production. Chicken eggs revolutionized the production of vaccines. Could animal stem cells be the new chicken egg? Vivalis has created a technology platform based on embryonic stem cells that enables the production of vaccines and antibodies. Vivalis’ CSO Majid Mehtali is interviewed by Reni Benjamin, analyst at Rodman & Renshaw. The business model is based on technology licensing, with future ambitions for own product development. Majid and Reni review comparables, Vivalis’ cash position, Euronext vs. NASDAQ listing, and the potential for acquisitions. This interview was conducted at the...

2008-07-1701 min

BioBusiness.TV, the podcast! ver2 Visionaries: Stelios Papadopoulos - Part 1You are Watching: Visionaries: Stelios on Financing, Productivity, and the Cost of Innovation. Stelios Papadopoulos, veteran of the Biotech Industry, looks at the financing environment today, and the "windowless paradigm" we've been operating in since 2003. He emphasizes the importance of changing investor sophistication and investment horizons. Stelios also addresses the cost of innovation and overall sector productivity. Finally Stelios looks back on his expectations for the market today, when he prepared them as an analyst 20 years ago. This interview was conducted at the NASDAQ Marketsite, on June 25th, 2008, in New York City. Featuring: * Stelios Papadopoulos, Chairman of the Board/Director...

2008-06-2509 min

BioBusiness.TV, the podcast! ver2 Visionaries: Stelios Papadopoulos - Part 2You are Watching: Stelios' 20 Year Vision, Fundamental Science, Personalized Medicine, and Energy. Stelios shares his vision for Biotech in the next 20 years, comparing technical and fundamental problems, how they will be funded and solved. He also addresses the issue of energy, for which he thinks we will find biologically driven solutions. Stelios discusses the relevance of personalized medicine, and his choice of investment today. This interview was conducted at the NASDAQ Marketsite, on June 25th, 2008, in New York City. Featuring: * Stelios Papadopoulos, Chairman of the Board/Director/Founder at Exelixis, Inc. * Jean-Loup Romet-Lemonne, President & CEO of BioBusiness.TV DISCLAIMER: BIOBUSINESS...

2008-06-2501 min